The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions
Phase 1
- Conditions
- Bioequivalence
- Interventions
- Drug: Aviga, capsules 50 mg / Sutent®, capsules 50 mgDrug: Sutent®, capsules 50 mg / Aviga, capsules 50 mg
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- JLLC NatiVita
- Target Recruit Count
- 22
- Registration Number
- NCT05218616
- Locations
- 🇧🇾
National Anti-Doping Laboratory, Lesnoy, Minsk Region, Belarus
© Copyright 2025. All Rights Reserved by MedPath